

Form 604
Corporations Act 2001
Section 671B

Notice of change of interests of substantial holder

To Company Name/Scheme Alterity Therapeutics Limited (formerly Prana Biotechnology Limited) ("Alterity")

ACN/ARSN 080 699 065

1. Details of substantial holder (1)

Name Life Biosciences LLC and each of its controlled entities listed in the Schedule (Controlled Entities)

ACN/ARSN (if applicable) Not applicable

There was a change in the interests of the substantial holder on

24 / 11 / 2020

The previous notice was given to the company on

26 / 10 / 2020

The previous notice was dated

26 / 10 / 2020

2. Previous and present voting power

The total number of votes attached to all the voting shares in the company or voting interests in the scheme that the substantial holder or an associate (2) had a relevant interest (3) in when last required, and when now required, to give a substantial holding notice to the company or scheme, are as follows:

Class of securities (4)	Previous notice		Present notice	
	Person's votes	Voting power (5)	Person's votes	Voting power (5)
Ordinary shares	269,905,533	19.9%	269,905,533	13.3%

3. Changes in relevant interests

Particulars of each change in, or change in the nature of, a relevant interest of the substantial holder or an associate in voting securities of the company or scheme, since the substantial holder was last required to give a substantial holding notice to the company or scheme are as follows:

Date of change	Person whose relevant interest changed	Nature of change (6)	Consideration given in relation to change (7)	Class and number of securities affected	Person's votes affected
24 / 11 / 2020	Life Biosciences LLC and its Controlled Entities listed in the Schedule	Decrease in relevant interest due to additional share issuances by the issuer	No consideration	N/A	N/A

4. Present relevant interests

Particulars of each relevant interest of the substantial holder in voting securities after the change are as follows:

Holder of relevant interest	Registered holder of securities	Person entitled to be registered as holder (8)	Nature of relevant interest (6)	Class and number of securities	Person's votes
Life Biosciences LLC and its Controlled Entities	Life Biosciences LLC	Life Biosciences LLC	Registered holder of Alterity Ordinary Shares	269,905,533	13.3%

5. Changes in association

The persons who have become associates (2) of, ceased to be associates of, or have changed the nature of their association (9) with, the substantial holder in relation to voting interests in the company or scheme are as follows:

Name and applicable ACN/ARSN (if applicable)	Nature of association
N/A	N/A

6. Addresses

The addresses of persons named in this form are as follows:

Name	Address
Alterity Therapeutics Limited	Level 3, 460 Bourke Street, Melbourne, Vic, 3000
Life Biosciences LLC	75 Park Plaza, 3 rd Floor, Boston MA 02116 USA
Controlled Entities of Life Biosciences LLC	See the Schedule

Signature

print name	Ivan Kaplan	capacity	Corporate counsel
sign here		date	30 November 2020

DIRECTIONS

- (1) If there are a number of substantial holders with similar or related relevant interests (eg. a corporation and its related corporations, or the manager and trustee of an equity trust), the names could be included in an annexure to the form. If the relevant interests of a group of persons are essentially similar, they may be referred to throughout the form as a specifically named group if the membership of each group, with the names and addresses of members is clearly set out in paragraph 6 of the form.
- (2) See the definition of "associate" in section 9 of the Corporations Act 2001.
- (3) See the definition of "relevant interest" in sections 608 and 671B(7) of the Corporations Act 2001.
- (4) The voting shares of a company constitute one class unless divided into separate classes.
- (5) The person's votes divided by the total votes in the body corporate or scheme multiplied by 100.
- (6) Include details of:
 - (a) any relevant agreement or other circumstances because of which the change in relevant interest occurred. If subsection 671B(4) applies, a copy of any document setting out the terms of any relevant agreement, and a statement by the person giving full and accurate details of any contract, scheme or arrangement, must accompany this form, together with a written statement certifying this
 - (b) any qualification of the power of a person to exercise, control the exercise of, or influence the exercise of, the voting powers or disposal of the securities to which the relevant interest relates (indicating clearly the particular securities to which the qualification applies).

See the definition of "relevant agreement" in section 9 of the Corporations Act 2001.
- (7) Details of the consideration must include any and all benefits, money and other, that any person from whom a relevant interest was acquired has, or may, become entitled to receive in relation to that acquisition. Details must be included even if the benefit is conditional on the happening or not of a contingency. Details must be included on any benefit paid on behalf of the substantial holder or its associate in relation to the acquisitions, even if they are not paid directly to the person from whom the relevant interest was acquired.
- (8) If the substantial holder is unable to determine the identity of the person (eg. if the relevant interest arises because of an option) write "unknown".
- (9) Give details, if appropriate, of the present association and any change in that association since the last substantial holding notice.

Schedule

The following entities are associates of Life Biosciences LLC as they are controlled by Life Biosciences LLC:

Name of Controlled Entity	Address of Controlled Entity
Animal Biosciences, Inc.	75 Park Plaza, Third Floor, Boston, MA 02116
Continuum Biosciences, Inc.	75 Park Plaza, Third Floor, Boston, MA 02116
Iduna Therapeutics, Inc.	75 Park Plaza, Third Floor, Boston, MA 02116
Jumpstart Fertility, Inc.	75 Park Plaza, Third Floor, Boston, MA 02116
Life Biosciences Inc.	75 Park Plaza, Third Floor, Boston, MA 02116
Life Lua Technologies, Inc.	75 Park Plaza, Third Floor, Boston, MA 02116
Selphagy Therapeutics, Inc.	75 Park Plaza, Third Floor, Boston, MA 02116
Senolytic Therapeutics, Inc.	75 Park Plaza, Third Floor, Boston, MA 02116

This is the Schedule of 1 page referred to in the Form 604, Notice of change of interests of substantial holder signed by me and dated 30 November 2020.



Ivan Kaplan
Corporate
Counsel Life
Biosciences
LLC